|
HY-P99115-10mg
|
MedChemexpress LLC
|
Envafolimab [CAS 2102192-68-5]
|
|
Cancer-programmed cell death
|
|
|
HY-P99115-5mg
|
MedChemexpress LLC
|
Envafolimab [CAS 2102192-68-5]
|
|
Cancer-programmed cell death
|
|
|
HY-P9984-1mg
|
MedChemexpress LLC
|
Etrolizumab [CAS 1044758-60-2]
|
|
Cancer-programmed cell death
|
|
|
HY-P9984-10mg
|
MedChemexpress LLC
|
Etrolizumab [CAS 1044758-60-2]
|
|
Cancer-programmed cell death
|
|
|
HY-P9984-5mg
|
MedChemexpress LLC
|
Etrolizumab [CAS 1044758-60-2]
|
|
Cancer-programmed cell death
|
|
|
HY-P99294-1mg
|
MedChemexpress LLC
|
Ganitumab [CAS 905703-97-1]
|
|
Cancer-Kinase/protease
|
|
|
HY-P99294-10mg
|
MedChemexpress LLC
|
Ganitumab [CAS 905703-97-1]
|
|
Cancer-Kinase/protease
|
|
|
HY-P99294-5mg
|
MedChemexpress LLC
|
Ganitumab [CAS 905703-97-1]
|
|
Cancer-Kinase/protease
|
|
|
HY-P99263-1mg
|
MedChemexpress LLC
|
Inclacumab [CAS 1256258-86-2]
|
|
Neuroscience-Neuromodulation
|
|
|
HY-P99263-10mg
|
MedChemexpress LLC
|
Inclacumab [CAS 1256258-86-2]
|
|
Neuroscience-Neuromodulation
|
|
|
HY-P99263-5mg
|
MedChemexpress LLC
|
Inclacumab [CAS 1256258-86-2]
|
|
Neuroscience-Neuromodulation
|
|
|
HY-P99670-1mg
|
MedChemexpress LLC
|
Iscalimab [CAS 2031153-61-2]
|
|
Metabolism-protein/nucleotide metabolism
|
|
|
HY-P99670-10mg
|
MedChemexpress LLC
|
Iscalimab [CAS 2031153-61-2]
|
|
Metabolism-protein/nucleotide metabolism
|
|
|
HY-P99670-5mg
|
MedChemexpress LLC
|
Iscalimab [CAS 2031153-61-2]
|
|
Metabolism-protein/nucleotide metabolism
|
|
|
HY-P99110-1mg
|
MedChemexpress LLC
|
Lanadelumab [CAS 1426055-14-2]
|
|
COVID-19-immunoregulation
|
|
|
HY-P99110-10mg
|
MedChemexpress LLC
|
Lanadelumab [CAS 1426055-14-2]
|
|
COVID-19-immunoregulation
|
|
|
HY-P99110-5mg
|
MedChemexpress LLC
|
Lanadelumab [CAS 1426055-14-2]
|
|
COVID-19-immunoregulation
|
|
|
HY-P99715-1mg
|
MedChemexpress LLC
|
Losatuxizumab [CAS 1801544-27-3]
|
|
Cancer-Kinase/protease
|
|
|
HY-P99715-10mg
|
MedChemexpress LLC
|
Losatuxizumab [CAS 1801544-27-3]
|
|
Cancer-Kinase/protease
|
|
|
HY-P99715-5mg
|
MedChemexpress LLC
|
Losatuxizumab [CAS 1801544-27-3]
|
|
Cancer-Kinase/protease
|
|
